Creo Medical Group PLC Director/PDMR Shareholding (4305Z)

TIDMCREO

RNS Number : 4305Z

Creo Medical Group PLC

31 August 2018

31 August 2018

Creo Medical Group plc

(the "Company")

Director/PDMR Dealing

Further to the completion of the Placing which occurred yesterday, and as detailed in the Company's announcement dated 13 July 2018, Craig Gulliford, Chief Executive Officer, and Chris Hancock, Chief Technology Officer, each sold 480,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") on 30 August 2018 at the Placing Price of GBP1.25 per Ordinary Share.

Following these trades, Mr Gulliford holds 609,886 Ordinary Shares representing approximately 0.51% of the Company's enlarged issued share capital and Mr Hancock holds 4,400,046 Ordinary Shares, representing approximately 3.67% of the Company's enlarged issued share capital.

Capitalised terms used, but not defined, in this announcement shall have the same meaning as set out in the Circular.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

 
 1    Details of the person discharging managerial responsibilities / person closely associated 
 a)   Name                                                          Craig Gulliford 
     ------------------------------------------------------------  ----------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------------------------------- 
 a)   Position/status                                               Chief Executive Officer 
     ------------------------------------------------------------  ----------------------------------- 
 b)   Initial notification /Amendment                               Initial 
     ------------------------------------------------------------  ----------------------------------- 
 3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
     ------------------------------------------------------------------------------------------------- 
 a)   Name                                                          Creo Medical Group plc 
     ------------------------------------------------------------  ----------------------------------- 
 b)   LEI                                                           213800H188ZDCWWXFA21 
     ------------------------------------------------------------  ----------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
     ------------------------------------------------------------------------------------------------- 
 a)   Description of the financial instrument, type of instrument    Ordinary shares of 0.1 pence each 
 
       Identification code 
                                                                      GB00BZ1BLL44 
     ------------------------------------------------------------  ----------------------------------- 
 b)   Nature of the transaction                                     Sale of Ordinary Shares 
     ------------------------------------------------------------  ----------------------------------- 
 c)   Price(s) and volume(s)                                          Price(s)    Volume(s) 
                                                                       GBP1.25     480,000 
                                                                                  ---------- 
     ------------------------------------------------------------  ----------------------------------- 
 d)   Aggregated information                                        n/a - single transaction 
 
 
       - Aggregated volume 
 
 
       - Price 
     ------------------------------------------------------------  ----------------------------------- 
 e)   Date of the transaction                                       30 August 2018 
     ------------------------------------------------------------  ----------------------------------- 
 f)   Place of the transaction                                      London Stock Exchange 
     ------------------------------------------------------------  ----------------------------------- 
 
 
 1    Details of the person discharging managerial responsibilities / person closely associated 
 a)   Name                                                          Chris Hancock 
     ------------------------------------------------------------  ----------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------------------------------- 
 a)   Position/status                                               Chief Technology Officer 
     ------------------------------------------------------------  ----------------------------------- 
 b)   Initial notification /Amendment                               Initial 
     ------------------------------------------------------------  ----------------------------------- 
 3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
     ------------------------------------------------------------------------------------------------- 
 a)   Name                                                          Creo Medical Group plc 
     ------------------------------------------------------------  ----------------------------------- 
 b)   LEI                                                           213800H188ZDCWWXFA21 
     ------------------------------------------------------------  ----------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
     ------------------------------------------------------------------------------------------------- 
 a)   Description of the financial instrument, type of instrument    Ordinary shares of 0.1 pence each 
 
       Identification code 
                                                                      GB00BZ1BLL44 
     ------------------------------------------------------------  ----------------------------------- 
 b)   Nature of the transaction                                     Sale of Ordinary Shares 
     ------------------------------------------------------------  ----------------------------------- 
 c)   Price(s) and volume(s)                                          Price(s)    Volume(s) 
                                                                       GBP1.25     480,000 
                                                                                  ---------- 
     ------------------------------------------------------------  ----------------------------------- 
 d)   Aggregated information                                        n/a - single transaction 
 
 
       - Aggregated volume 
 
 
       - Price 
     ------------------------------------------------------------  ----------------------------------- 
 e)   Date of the transaction                                       30 August 2018 
     ------------------------------------------------------------  ----------------------------------- 
 f)   Place of the transaction                                      London Stock Exchange 
     ------------------------------------------------------------  ----------------------------------- 
 

Contacts

 
 Creo Medical:                   Cenkos:                                   FTI Consulting: 
 Richard Rees                    Mark Connelly (NOMAD)                     Brett Pollard / Mo Noonan 
  [phone]             Michael Johnson / Russell Kerr (Sales)    [phone] 
  [e-mail]    [phone]                       [e-mail] 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHLLFFITTILVIT

(END) Dow Jones Newswires

August 31, 2018 06:30 ET (10:30 GMT)